ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2018

Abstract Number: 1067

Simulating the Pathogenesis of Arthritis in Vitro By Developing a Human-Based Multicomponent 3D Joint Model

Alexandra Damerau1,2, Annemarie Lang1,2, Moritz Pfeiffenberger1,2, Timo Gaber1,3 and Frank Buttgereit1,2, 1Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, 2Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, 3Deutsches Rheuma Forschungszentrum (DRFZ) Berlin, Berlin, Germany

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2018

Keywords: Bone, cartilage, Cell Migration, rheumatoid arthritis (RA) and synovial cells, synovial fluid

Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Etiology and Pathogenesis Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Although arthritis is a matter of research since more than 140 years, there is currently no valid 3D model available, which is able to mimic an inflamed joint. Thus, our ultimate goal is to develop a valid human in vitro 3D joint model in order to simulate arthritis. The model will contain all involved tissue components and cell types enabling the interactions between cells by cell contacts, signaling molecules and metabolites. As an alternative experimental setup for traditional animal models, our in vitro model will enable us to study the influence and efficacy of drug treatment.

To this end, we firstly developed all single components of the joint, namely the (1) osteogenic and (2) chondrogenic part, (3) the joint space with synovial fluid and (4) the synovial membrane, separately.

Methods: The osteogenic component was synthesized by seeding human bone marrow-derived mesenchymal stromal cells (hMSC) on β-tricalcium phosphate (TCP) coated with an additional hMSC monolayer cell-sheet and cultured for a total of 6 weeks. Survival, adhesion and structural integrity of the cells were evaluated by Scanning Electron Microscopy (SEM), LIVE/DEAD staining and cellular release of LDH. Osteogenic differentiation was analyzed both by µCT for mineralization and on gene expression level using qPCR. To mimic the chondrogenic part, a scaffold-free 3D cartilage construct was generated by chondrogenic differentiation of hMSC with intermittent mechanical stimulation. Constructs were analyzed by histology and qPCR. Non-animal stabilized hyaluronic acid was used to simulate the synovial fluid component. In order to model the synovial membrane, hMSC were differentiated towards the fibroblast lineage and then a confluent layer was formed on a polycarbonate membrane, which was visualized by histology.

Results: We developed an in vitro 3D osteogenic model by successfully seeding hMSC on a β-TCP scaffold. Cells consistently adhere onto the scaffold for up to 6 weeks as observed by SEM. The analysis of cell viability via LDH detection and LIVE/DEAD staining showed no toxic effects on the cells as compared to the corresponding control. Osteogenic differentiation of hMSC grown in 3D was verified demonstrating an increase in mineralized bone volume and the induction of bone-related gene expression (RUNX2, SPP1 and COL1A1) as compared to the corresponding control. Chondrogenic phenotype was verified by HE and Alcian Blue staining as well as by the reduced expression of COL1A1 and an abundant expression of COL2A1. Interestingly, co-cultivation of the osteogenic and chondrogenic part for up to 3 weeks demonstrated successful colonization, connectivity and initial calcification implying a functional transitional bridging area. Modelling the synovial membrane, we successfully and reproducibly created a confluent monolayer of hMSC, which is easily transferable to the model.

Conclusion: In summary, we confirmed and validated in a standardized manner phenotypic integrity and stability of each single component. To finalize the development of healthy joint model we will combine the established parts to provide suitable 3D joint model that enables us to study the efficacy of drug treatment in vitro.


Disclosure: A. Damerau, None; A. Lang, None; M. Pfeiffenberger, None; T. Gaber, None; F. Buttgereit, Amgen, Roche/Chugai, GSK, BMS, Pfizer, Medac, Horizon, Mundipharma, 2,Medac, Mundipharma, Celgene, Horizon, 2,Sanofi, Pfizer, BMS, 5,Lilly, Abbvie, Pfizer, UCB, Roche, 8.

To cite this abstract in AMA style:

Damerau A, Lang A, Pfeiffenberger M, Gaber T, Buttgereit F. Simulating the Pathogenesis of Arthritis in Vitro By Developing a Human-Based Multicomponent 3D Joint Model [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/simulating-the-pathogenesis-of-arthritis-in-vitro-by-developing-a-human-based-multicomponent-3d-joint-model/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/simulating-the-pathogenesis-of-arthritis-in-vitro-by-developing-a-human-based-multicomponent-3d-joint-model/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology